Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
3(25%)
Results Posted
100%(8 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
3
25%
Ph phase_3
5
42%
Ph phase_4
2
17%
Ph phase_2
2
17%

Phase Distribution

3

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
3(25.0%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
5(41.7%)
Phase 4Post-market surveillance
2(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(3)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Active, not recruiting2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (25.0%)
Phase 22 (16.7%)
Phase 35 (41.7%)
Phase 42 (16.7%)

Trials by Status

active_not_recruiting217%
recruiting18%
completed867%
terminated18%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT03035331Phase 1

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Completed
NCT03942328Phase 1

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Recruiting
NCT06647407Phase 1

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Active Not Recruiting
NCT02518555Phase 2

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active Not Recruiting
NCT04080531Phase 4

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Completed
NCT03537508Phase 3

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Completed
NCT04535037Phase 4

A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

Completed
NCT03691610Phase 3

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Completed
NCT03673462Phase 3

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Completed
NCT03630705Phase 3

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico

Completed
NCT02309515Phase 2

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

Terminated
NCT01218451Phase 3

NeisVac-C Single Prime Study in Infants

Completed

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12